Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Astrotech reports a substantial revenue growth to $1.54 million

EditorLina Guerrero
Published 02/12/2024, 05:39 PM
Updated 02/12/2024, 05:39 PM
© Reuters.

AUSTIN, Texas - Astrotech (NASDAQ:ASTC) Corporation (NASDAQ:ASTC), a mass spectrometry company, announced a substantial increase in its year-to-date revenue, which climbed to $1.54 million, marking a 512% rise compared to the same period last year. The company attributed this growth primarily to the successful fulfillment of two large orders for its TRACER 1000™ explosive trace detectors (ETDs) in Romania.

The financial results for the second quarter of fiscal year 2024, ending December 31, 2023, also revealed an improved gross margin, which increased from 38% to 46%. Astrotech's consolidated balance sheet shows a strong position with $37 million in cash and liquid investments, anticipated to support ongoing research and development, organic growth, and potential acquisition targets.

Astrotech's subsidiary, 1st Detect, has reentered testing with the U.S. Transportation Security Administration (TSA) for cargo security after the quarter ended. The TRACER 1000 is undergoing approval processes to be listed as an approved device for cargo screening in the United States.

Additionally, Astrotech launched a new subsidiary, Pro-Control, Inc., on December 12, 2023, which applies the company's mass spectrometry technology to chemical manufacturing process control. The Pro-Control-1000™ mass spectrometer is designed to test and enhance potency, purity, and yields in chemical manufacturing processes.

The company's AgLAB division continues production and sales efforts for the AgLAB 1000-D2™, which was showcased at the MJ BizCon event held in the second quarter of fiscal year 2024. Thomas B. Pickens III, Chairman and CEO of Astrotech, expressed optimism about the traction gained in the checkpoint market and the positive feedback from customers regarding the TRACER 1000's performance.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Astrotech emphasized that while product development carries inherent risks and uncertainties, it is progressing with its new products, including the AgLAB-1000, BreathTest-1000, and Pro-Control-1000. However, it noted that FDA approval is required for the BreathTest-1000, and there can be no assurance of a successful or timely approval.

The financial results presented are based on a press release statement from Astrotech Corporation. The company operates through its subsidiaries, developing and commercializing technology for security, detection, agriculture, and chemical process control markets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.